Cassava Sciences initiates phase 2b clinical study in Alzheimer’s patients
Cassava Sciences reported initiation of a Phase 2b study of its lead drug candidate, PTI-125, in Alzheimer’s patients. PTI-125 is a small molecule that targets the massive neuroinflammation and neurodegeneration observed in the Alzheimer’s brain. September 16, 2019